Ahmed Fida, MD
Family Medicine · Bealeton, VANPI 1962722157
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Novo Nordisk at 27.6% of the total. Reporting peaked in 2023 at $503 and has fallen 60.2% since, to $200 in 2025.
Across 98 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$477
- AbbVie$324
- Abbott$136
- Lilly USA, LLC$102
- Exact Sciences$101
- GSK$78
- plus $510 from 16 others
What the payments were for
- Food & beverage$1,728100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $477 |
| AbbVie(2 entities) | 19 | $324 |
| Abbott | 6 | $136 |
| Lilly USA, LLC | 7 | $102 |
| Exact Sciences | 4 | $101 |
| GSK | 4 | $78 |
| Pfizer | 5 | $69 |
| Boehringer Ingelheim | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| AstraZeneca | 3 | $46 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Amarin Pharma, Inc. | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Amgen | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Gilead | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$1,728 in reported general payments places this provider in the 75th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 118 | $136,320 |
| OzempicSemaglutide | 60 | $93,715 |
| TrulicityDulaglutide | 39 | $73,999 |
| EliquisApixaban | 34 | $39,805 |
| JanuviaSitagliptin Phosphate | 27 | $32,269 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $27,510 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $27,350 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $12,931 |
| Spiriva RespimatTiotropium Bromide | 13 | $12,689 |
| FarxigaDapagliflozin Propanediol | 12 | $11,848 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $9,339 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $8,783 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $8,362 |
| Repatha SureclickEvolocumab | 13 | $7,162 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $6,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat, Tradjenta | $62 | $163,784162 claims |
| Novo NordiskOzempic | $477 | $93,71560 claims |
| Lilly USA, LLCTrulicity, Cymbalta | $102 | $77,64953 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $46 | $45,85854 claims |
| PfizerEliquis | $69 | $39,80534 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $78 | $35,71250 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Bealeton
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- Jordan TranWinchester$42K
- John ClayColonial Heights$40K
- Thomas RobesonNewport News$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.